Kuwait, Bahrain Approves 'Sotrofimab' For COVID Victims

Kuwait and Bahrain have approved the use of Sotrofimab as a treatment for the coronavirus.

The GSK and Vir Biotechnology created drug can be used for the treatment of  mild to moderate cases of COVID-19, state agencies KUNA and Bahrain News Agency reported.

The UAE also approved the drug’s use earlier in the week.

Research has shown the use of the drug leads to a reduction in the number of cases requiring hospitalization for more than 24 hours and a reduction in the number fatalities by 85 percent, when administered at an early stage of treatment.

Meanwhile Kuwait has also announced on Wednesday a $40 million donation to COVAX, the international program designed to help supply developing countries with vaccines against the disease, KUNA said.

This article has been adapted from its original source.